UroGen Pharma Ltd. - Ordinary Shares (URGN) News

UroGen Pharma Ltd. - Ordinary Shares (URGN): $9.97

-0.73 (-6.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add URGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 373

in industry

Filter URGN News Items

URGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

URGN News Highlights

  • URGN's 30 day story count now stands at 9.
  • Over the past 27 days, the trend for URGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about URGN are BEAT and GEL.

Latest URGN News From Around the Web

Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.

With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the...

Yahoo | May 22, 2023

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript May 11, 2023 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-1.3, expectations were $-1.33. Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded. […]

Yahoo | May 16, 2023

Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2023

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

PRINCETON, N.J., May 11, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments.

Yahoo | May 11, 2023

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

PRINCETON, N.J., May 04, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2023 first quarter financial results on Thursday, May 11, 2023, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Yahoo | May 4, 2023

Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 2, 2023

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

PRINCETON, N.J., May 01, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyceal solution presented today at the American Urological Association Meeting 2023 in Chicago, IL. The study titled, "Efficacy and Safety of Mitomycin Gel (UGN-10

Yahoo | May 1, 2023

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

PRINCTON, N.J., April 30, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® (mitomycin) for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL. The study titled, First Analysis of the Safety and Efficacy of UGN-

Yahoo | April 30, 2023

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

PRINCETON, N.J., April 25, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May 2, 2023 at 10:00 AM ET.

Yahoo | April 25, 2023

UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares

With a price-to-sales (or "P/S") ratio of 3.5x UroGen Pharma Ltd. ( NASDAQ:URGN ) may be sending very bullish signals...

Yahoo | April 18, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6206 seconds.